In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days

Andrea Cervi,James D. Douketis

In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days

2019

Andrea Cervi
James D. Douketis

Source Citation Khorana AA, Soff GA, Kakkar AK, et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720-8 30786186

Keywords:

Diabetes mellitus
Cancer
Rivaroxaban
Internal medicine
Cardiology
Medicine
Ambulatory
venous thromboembolism
high risk patients

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations